Aprea Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview

Aprea Therapeutics

08/08/2025 18:44

Aprea Therapeutics Inc APRE.OQ APRE.O is expected to  show a fall in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Aprea Therapeutics Inc is for a loss of 74 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".​

Wall Street's median 12-month price target for Aprea Therapeutics Inc is $10.50, about 84.3% above its last closing price of $1.65

This summary was machine generated August 8 at 17:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)